Cytovance Adds Perfusion Capabilities

Editor’s Take: This latest investment builds on Cytovance’s recent expansion of in-house cell line development and formulation development services.

Cytovance Biologics, a U.S.-based contract development and manufacturing organization (CDMO), has expanded its upstream process development offerings with the addition of perfusion capabilities.

“Our goal is to continue expanding the technologies and expertise available to clients as the industry evolves,” said Fuad Haddadin, Ph.D., Head of Research & Development at Cytovance Biologics. “By integrating perfusion into our development platform, we’re giving sponsors greater flexibility while positioning Cytovance to support the future of biologics manufacturing.”

Unlike traditional fed-batch processes, perfusion continuously replenishes fresh media while removing spent media, allowing cell cultures to remain healthy and productive for significantly longer periods. The approach can improve productivity, maintain more consistent culture conditions, and reduce the accumulation of metabolic byproducts that may impact product quality.

The addition of perfusion capabilities enables Cytovance to support clients evaluating different upstream manufacturing strategies for monoclonal antibodies, recombinant proteins, and other biologic modalities, particularly during early process development.

“Perfusion is not intended to replace fed-batch manufacturing; it’s another tool that allows us to develop the right process for each client’s program,” said Charles Oluremi Solanke, Senior Scientist, Upstream Process Development at Cytovance Biologics. “By expanding our expertise in both approaches, we’re able to help companies optimize productivity, improve process consistency, and prepare programs for long-term manufacturing success.”